Mio’s Story: How Psilocybin Therapy For End-Of-Life Anxiety Helps To Treat The Whole Person
Last reviewed and updated: July 1, 2026.
Key Takeaways
| NYU/Hopkins data | Single psilocybin session → significant lasting reduction in death anxiety + depression in terminal cancer patients; effects sustained at 6 months; effect sizes larger than typical antidepressants |
| Current legal access | Oregon service centers available NOW for end-of-life anxiety — no trial enrollment required; $500–$2,500/session arc |
| What the experience involves | Preparation sessions + 6–8 hour psilocybin session with trained facilitator + integration; mystical experience depth is the strongest predictor of outcome |
| The “whole person” frame | Palliative care + psychedelic therapy integration growing; Memorial Sloan Kettering now has formal psychedelic therapy research program |
| Compass NDA context | Psilocybin regulatory path being established; end-of-life indication expected as an early priority once first approval clears |
Research shows that for patients suffering from life-threatening cancer, complementary therapies ranging from yoga to qigong and psychedelic-assisted therapy can help treat cancer-related side effects like pain, fatigue, anxiety, and depression. And one option growing in popularity is psilocybin therapy for anxiety.
Yes, Western medicine can treat most symptoms and ailments with precision. But when it comes to holistic therapy, the healthcare system tends to overlook the connection between mind, body, and spirit. This is opening the door for patients to explore other, more natural treatment methods.
RELATED: What Does Anxiety Feel Like?
Existential Anxiety ‘Like An Underlying Rumbling’
Mio Yokoi, a therapist in her mid-40s, was diagnosed with stage-four pancreatic cancer two years ago. At the time, doctors told her that they weren’t sure how much time she had left to live. She knew then that, in addition to treating the cancer, she would also have to take care of her mind.
“I wanted to make sure to think about my mental and emotional health as well, so I signed up for every resource I could get my hands on in terms of psychosocial support,” Yokoi told Healing Maps.
The resources helped, she said, but she still felt overcome with existential dread and fear. She described the feeling as “an underlying rumbling, a kind of stormy internal sense” that robbed her of the peace she felt before receiving her diagnosis.
“All of a sudden, that finish line seems a lot closer, and it’s really difficult to be able to internally organize all of that and find some kind of peace,” she said. “It was really impacting my quality of life.”
She had heard about the research behind psilocybin therapy for anxiety — specifically for end-of-life distress. However, she wasn’t sure it was something she could access safely.
Then, last fall, Yokoi learned that the Toronto hospital network where her cancer was being treated had received a substantial donation to create a psychedelic research center. Here, psilocybin and other psychedelic drugs would be studied for end-of-life distress and treatment-resistant depression.
She contacted staff at the hospital to inquire about the status of the studies and if she was qualified to participate but learned that it would be several months before research began. “I realized that I didn’t know if I was going to be around long enough to benefit from this thing, and I decided to see whether or not there were private options,” said Yokoi.
RELATED: Should “Healthy” People Take Psychedelics?
Field Trip Health Helps With Access To Psilocybin Therapy For Anxiety
In her search for legal access to psilocybin, she found Field Trip Health, a psychedelic medicine clinic in Toronto that had recently posted some information online about Canada’s Special Access Program (SAP). The SAP allows physicians to request access to restricted drugs, including drugs that have shown promise in clinical trials, on behalf of patients with serious or life-threatening conditions.
Through her interest in mental health and psychedelics, Yokoi was already familiar with Field Trip. “I knew that they were a clinic and a company providing this service, with experience and safety protocols, so that’s something I felt good about,” she said.
She recruited Field Trip’s medical director, Dr. Michael Verbora, to help her apply for special access to psilocybin. While they waited for a response from Health Canada, Yokoi decided to try ketamine-assisted therapy.
“Ketamine already works for treatment-resistant depression, it’s got great evidence in a whole host of mental health conditions, and it’s extremely safe to use — we have tens of thousands of data points, and zero adverse outcomes,” Verbora told Healing Maps in a separate interview.
“They were very different experiences,” Yokoi said. “I know now that different psychedelic substances can have different uses, and very different experiences — they can’t all just be lumped under the same umbrella.”
According to Mio, ketamine makes her feel “warm and floaty, like a hug.” Yokoi says ketamine makes her feel completely dissociated from her body. Still, she feels comfortable and safe during the relatively short experience — effects of sublingual ketamine typically last 90 minutes.
Psilocybin Therapy Goes Deep
“With the psilocybin, it was much deeper and grander… there were a lot of lessons that came out of it,” she said of the four-hour experience. One thing that the session brought to the surface was Yokoi’s relationship with her body.
“My physical self is a necessary partner in life, but somehow I’ve always kind of been unsure, and not quite trusting of what my body is doing, especially now with the diagnosis that I have,” she said. “It didn’t necessarily provide me with answers, but it certainly gave me this gift, like, ‘hey, you’re not looking at this.’”
Throughout her session, Yokoi felt the urge to move her body and to ground herself using practices like stretching and yoga. She adds: “Every nerve in my body felt like it needed to move, so it was a very active session.
Using psilocybin therapy for anxiety also illuminated the nature of her fear towards death.
“[It showed me] as much as I try to educate myself about what end-of-life could look like, I still have no idea what to expect in terms of what’s going to happen to me,” she said. “I’m afraid that I won’t be able to handle it, and I’m also afraid that people, life, the universe, whatever — won’t be there to take care of me.”
Yokoi intends to follow up with a second psilocybin treatment to revisit some of what she learned during her first session. However, since she is participating in a clinical trial for a new cancer treatment, she has yet to schedule time with Dr. Verbora.
“The last experience, as remarkable as it was, was really intense, and I’m still processing quite a bit from it.”
RELATED: Psilocybin Laws In Colorado And Oregon: What’s The Difference?
SAP Program ‘Worth Exploring’
When asked what advice she might offer to other patients interested in trying psilocybin therapy for anxiety, Yokoi said people shouldn’t consider trying it without access to the right kind of support.
“It’s crucial to be working with people who understand these substances, the protocols, the dosing, and the therapeutic aspects of treatment,” she said. “That’s a lot of stuff to figure out on one’s own, and could also potentially be quite a traumatic experience.”
Yokoi emphasizes that, for patients like her struggling with a serious cancer diagnosis, psilocybin therapy for anxiety “is worth investigating and exploring.” In her experience, going through SAP allows a person to treat more than just their disease.
“When people have this kind of diagnosis and they are in the situation that I am in, there may be more of a focus on just treating the physical. But the mental, emotional, and spiritual parts of us are just as important,” she said. “Western oncologists aren’t necessarily going to say that survival or longevity have anything to do with taking care of one’s mental health. But it’s part of who we are.”
End-of-Life Psilocybin Therapy in 2025–2026: From Experimental to Expanding Access
When Mio’s story was first published, psilocybin therapy for end-of-life anxiety was available only through clinical trials at a handful of research institutions. The landscape has changed substantially. The evidence base has deepened, legal access has opened in Oregon, and what was once described as “whole person” care has become a recognized framework in mainstream palliative medicine. The broad arc of what Mio experienced — a single psilocybin session producing a sustained change in her relationship with death — has now been replicated in multiple rigorous studies with hundreds of participants.
What NYU and Johns Hopkins found: large effects, sustained. Two of the most important psilocybin studies ever published focused specifically on existential distress in people with life-threatening cancer diagnoses. The landmark studies from NYU Langone and Johns Hopkins Medicine — published together in Journal of Psychopharmacology in 2016 — found that a single psilocybin session produced large, statistically significant reductions in depression and death anxiety in terminal cancer patients. Effect sizes were dramatically larger than what is typically seen with antidepressants. At 6-month follow-up, the majority of participants retained meaningful benefit, with many reporting it among the most significant experiences of their lives. Follow-up studies have confirmed durability: these are not effects that fade in weeks. For a population facing terminal illness for whom existing psychopharmacology offers limited benefit and significant side effects, these data represent a meaningful clinical development.
Legal access now exists — and it includes end-of-life patients. Oregon’s licensed psilocybin service centers, which began operating in 2023, can serve adults including those with terminal illness — without requiring enrollment in a clinical trial. This is a significant development. The Oregon model does not require a diagnosis or a therapist referral; any adult can access licensed psilocybin services. A full session (preparation, 6–8 hour psilocybin experience with a licensed facilitator, integration) typically costs $500–$2,500 depending on the provider and format. For terminally ill patients who cannot access academic medical center trials and cannot afford the cost of international options (Jamaica, Netherlands), Oregon now offers a domestic legal pathway. Colorado’s regulated framework, which launched in 2024, is adding additional licensed providers.
The “whole person” frame has become mainstream palliative care practice. The integration of psychedelic-assisted therapy with palliative care is no longer a fringe concept. Memorial Sloan Kettering Cancer Center — one of the world’s leading cancer treatment institutions — now has a formal psychedelic therapy research program focused specifically on cancer patients, including those with existential distress and end-of-life anxiety. Field Trip Health, where Mio had her experience, has since restructured and rebranded; the broader clinic landscape has consolidated. But the providers who remain are more established, better regulated in Oregon, and increasingly integrated with conventional oncology and palliative care teams. What Mio’s story captured — the possibility of a different relationship with death after a single guided experience — is now being systematically documented, replicated, and extended.
Frequently Asked Questions
Is psilocybin therapy available for people with terminal illness?
Yes, with important nuance. In Oregon, licensed psilocybin service centers are legally authorized to serve any adult, including those with terminal illness, without requiring a clinical trial enrollment or a specific diagnosis. This is currently the most accessible domestic legal pathway for end-of-life psilocybin therapy in the United States. Colorado’s licensed framework, which launched in 2024, is adding additional providers. Outside the US, retreats in Jamaica (where psilocybin is unscheduled) and licensed therapy centers in the Netherlands are established options. Clinical trials at institutions like Johns Hopkins and NYU have historically been available to patients with life-threatening diagnoses, but enrollment is limited and competitive. The Oregon service center model is the most open-access option currently available.
What does psilocybin therapy for end-of-life anxiety involve?
A typical psilocybin therapy session for existential distress involves three phases. Preparation: one or more sessions with a trained facilitator to build therapeutic alliance, discuss intentions, address fears, and prepare for the experience. The psilocybin session itself: typically 6–8 hours in a comfortable, private setting — reclining, with eyeshades and music, with one or two trained facilitators present throughout. The dose used in end-of-life research has typically been 25–30mg of synthetic psilocybin (a moderate-to-high dose). Participants are encouraged to surrender to the experience rather than resist it. Integration: one or more follow-up sessions to process what arose, make meaning, and apply insights to daily life and to their relationship with death. In the Oregon service center model, preparation and integration are required components of every session. The full arc — including preparation, session, and integration — typically spans 4–8 weeks.
What does the research say about psilocybin for death anxiety?
The evidence is among the strongest in the psilocybin research field. Landmark studies from NYU Langone and Johns Hopkins Medicine (published together in 2016) found that single psilocybin sessions produced large reductions in depression and death anxiety in terminal cancer patients — effect sizes significantly larger than those typically seen with SSRIs or benzodiazepines. At 6-month follow-up, the majority of participants retained meaningful benefit. Follow-up work has confirmed durability and found that the depth of the mystical or peak experience during the session was the strongest predictor of therapeutic outcome — not the dose itself. Subsequent work has extended these findings to patients with other life-threatening diagnoses. The FDA has granted psilocybin Breakthrough Therapy designation for major depressive disorder and treatment-resistant depression; end-of-life indications are expected to be among the early priority applications once the first psilocybin therapy is approved.
How do I access psilocybin therapy for a loved one with terminal illness?
The most practical pathway in the United States is Oregon’s licensed psilocybin service center network. Any adult can access these services without a diagnosis, referral, or trial enrollment. Start by searching for licensed Oregon psilocybin service centers through the Oregon Health Authority’s public registry of licensed facilitators and service centers. When evaluating providers, ask about their experience with end-of-life populations specifically, the structure of their preparation and integration support, and their facilitator training background. Cost is typically $500–$2,500 for a full session arc. For patients who cannot travel, clinical trials at institutions including Johns Hopkins, NYU, and other academic medical centers may offer access — check ClinicalTrials.gov for currently enrolling studies. International options (Jamaica, Netherlands) exist for those with resources to travel. A palliative care physician or integrative oncologist who is knowledgeable about psychedelic therapy can help evaluate candidacy and coordinate care.
